Magnetar Financial LLC
Institutional investor · Portfolio as of Q2 2023
Top Holdings476 positions
Abbott Laboratories | 950,603 | $103.6M | 2.3% | $94.20 | +8.20% | 2 qtrssince 2023-Q1 | Decreased 0 |
NuVasive Inc | 2.4M | $100.9M | 2.2% | — | — | 4 qtrssince 2022-Q3 | Increased 67 |
Albertsons Cos Inc | 4.6M | $99.9M | 2.2% | $19.29 | +5.56% | 3 qtrssince 2022-Q4 | Increased 62 |
Univar Inc | 2.8M | $99.7M | 2.2% | — | — | 2 qtrssince 2023-Q1 | Decreased 0 |
FOCUS FINL PARTNERS INC | 1.8M | $95M | 2.1% | — | — | 2 qtrssince 2023-Q1 | Increased 68 |
Aerojet Rocketdyne Holdings In | 1.7M | $92.8M | 2.0% | — | — | 3 qtrssince 2022-Q4 | Decreased 0 |
PNM Resources Inc | 2M | $89.2M | 2.0% | $40.61 | -0.36% | 11 qtrssince 2020-Q4 | Increased 48 |
Churchill Capital Corp VII | 8.3M | $85.7M | 1.9% | — | — | 6 qtrssince 2022-Q1 | Decreased 0 |
Triton International Ltd/Bermu | 1M | $84.3M | 1.8% | — | — | 1 qtr | New 68 |
Radius Global Infrastructure I | 5.4M | $80.5M | 1.8% | — | — | 2 qtrssince 2023-Q1 | Decreased 0 |
PDC Energy Inc | 1.1M | $76.6M | 1.7% | — | — | 1 qtr | New 68 |
Encompass Health Corp | 1.1M | $76.5M | 1.7% | $50.82 | +29.22% | 6 qtrssince 2022-Q1 | Decreased 0 |
Merck & Co Inc | 653,931 | $75.5M | 1.7% | $83.67 | +25.55% | 7 qtrssince 2021-Q4 | Decreased 0 |
ARCONIC CORP | 2.4M | $71.9M | 1.6% | — | — | 1 qtr | New 68 |
Baxter International Inc | 1.5M | $68.1M | 1.5% | $53.10 | -20.83% | 17 qtrssince 2019-Q2 | Increased 55 |
IVERIC bio Inc | 1.7M | $65.6M | 1.4% | — | — | 1 qtr | New 67 |
Life Storage Inc | 492,471 | $65.5M | 1.4% | — | — | 1 qtr | New 67 |
Activision Blizzard Inc | 757,561 | $63.9M | 1.4% | — | — | 6 qtrssince 2022-Q1 | Decreased 0 |
Seattle Genetics Inc | 328,246 | $63.2M | 1.4% | — | — | 2 qtrssince 2023-Q1 | Increased 54 |
GSK PLC-SPON ADR | 1.8M | $63M | 1.4% | $27.82 | +15.09% | 4 qtrssince 2022-Q3 | Increased 54 |
Magnetar Financial LLC manages $4.6B across 476 positions as of Q2 2023. Top holdings: ABT (2.3%), NUVA (2.2%), ACI (2.2%). Fund DNA: Momentum Trader. HoldingsIntel Score: 3/5.0.
Active quarter - 179 new positions, 300 exits, 83 increased. Top move: FOCS (INCREASED, conviction 68). Portfolio: $4.6B across 476 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR